Skip to content

Study · Animal study (in vivo) · rat · 1995

14 results

Comparison of the effects of intermittent and continuous administration of human parathyroid hormone(1-34) on rat bone.

Uzawa T, Hori M, Ejiri S, Ozawa H

Bone1 Apr 1995Cited by 118 (Europe PMC)

PMID7605709 (opens in a new tab)DOI10.1016/8756-3282(95)90194-9 (opens in a new tab)PepBankPUB-07605709
Publisher pagePubMedAsk about this study
Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats, continuous hPTH(1-34) infusion decreased femoral dry weight dose dependently.

    In plain wordsIn rats, continuous hPTH infusion decreased thigh bone dry weight with increasing dose.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseFemoral dry weight with continuous infusion
    Study

    ratn: not reported in source

    Rat bone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · continuous infusion · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    Continuous infusion of hPTH(1-34) caused a dose-dependent decrease in the dry weight of the femur and a hyperparathyroidism-like condition in the high-dose group (214 ng/kg/h).
    1 context sentence
    Summary · context
    We compared the effects of synthetic human parathyroid hormone (1-34) (hPTH[1-34]) on rat bones when administered by intermittent injection and by continuous infusion for 4 weeks.
  2. 02AnimalAnimal study (in vivo)Safety outcome

    In rats, high-dose continuous hPTH(1-34) infusion caused a hyperparathyroidism-like condition.

    In plain wordsIn rats, high-dose continuous hPTH infusion caused a condition resembling excessive parathyroid activity.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseHyperparathyroidism-like condition
    Study

    ratn: not reported in source

    Rat bone
    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    214 ng/kg/h · continuous infusion · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    Continuous infusion of hPTH(1-34) caused a dose-dependent decrease in the dry weight of the femur and a hyperparathyroidism-like condition in the high-dose group (214 ng/kg/h).
    1 context sentence
    Summary · context
    We compared the effects of synthetic human parathyroid hormone (1-34) (hPTH[1-34]) on rat bones when administered by intermittent injection and by continuous infusion for 4 weeks.
  3. 03AnimalAnimal study (in vivo)Safety outcome

    In rats, high-dose continuous hPTH(1-34) infusion produced markedly abnormal bone morphology.

    In plain wordsIn rats, high-dose continuous hPTH infusion produced markedly abnormal bone structure.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseAbnormal bone morphology
    Study

    ratn: not reported in source

    Rat bone
    Outcome group
    Adverse events · Musculoskeletal
    Studied dose
    214 ng/kg/h · continuous infusion · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    In this group, although bone morphology was quite abnormal, the metaphyseal trabecular bone volume increased, whereas the epiphyseal trabecular bone volume tended to decrease, enhancing both bone resorption and formation.
    2 context sentences
    Summary · context
    Continuous infusion of hPTH(1-34) caused a dose-dependent decrease in the dry weight of the femur and a hyperparathyroidism-like condition in the high-dose group (214 ng/kg/h).
    Summary · context
    We compared the effects of synthetic human parathyroid hormone (1-34) (hPTH[1-34]) on rat bones when administered by intermittent injection and by continuous infusion for 4 weeks.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats, high-dose continuous hPTH(1-34) infusion increased metaphyseal trabecular bone volume.

    In plain wordsIn rats, high-dose continuous hPTH infusion increased spongy bone volume in the metaphysis.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseMetaphyseal trabecular bone volume with infusion
    Study

    ratn: not reported in source

    Rat bone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    214 ng/kg/h · continuous infusion · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    In this group, although bone morphology was quite abnormal, the metaphyseal trabecular bone volume increased, whereas the epiphyseal trabecular bone volume tended to decrease, enhancing both bone resorption and formation.
    2 context sentences
    Summary · context
    Continuous infusion of hPTH(1-34) caused a dose-dependent decrease in the dry weight of the femur and a hyperparathyroidism-like condition in the high-dose group (214 ng/kg/h).
    Summary · context
    We compared the effects of synthetic human parathyroid hormone (1-34) (hPTH[1-34]) on rat bones when administered by intermittent injection and by continuous infusion for 4 weeks.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats, epiphyseal trabecular bone volume tended to decrease with high-dose continuous hPTH(1-34) infusion.

    In plain wordsIn rats, spongy bone volume in the epiphysis tended to decrease with high-dose continuous hPTH infusion.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseEpiphyseal trabecular bone volume with infusion
    Study

    ratn: not reported in source

    Rat bone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    214 ng/kg/h · continuous infusion · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    In this group, although bone morphology was quite abnormal, the metaphyseal trabecular bone volume increased, whereas the epiphyseal trabecular bone volume tended to decrease, enhancing both bone resorption and formation.
    2 context sentences
    Summary · context
    Continuous infusion of hPTH(1-34) caused a dose-dependent decrease in the dry weight of the femur and a hyperparathyroidism-like condition in the high-dose group (214 ng/kg/h).
    Summary · context
    We compared the effects of synthetic human parathyroid hormone (1-34) (hPTH[1-34]) on rat bones when administered by intermittent injection and by continuous infusion for 4 weeks.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats, high-dose continuous hPTH(1-34) infusion enhanced bone resorption.

    In plain wordsIn rats, high-dose continuous hPTH infusion increased bone breakdown.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone resorption with infusion
    Study

    ratn: not reported in source

    Rat bone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    214 ng/kg/h · continuous infusion · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    In this group, although bone morphology was quite abnormal, the metaphyseal trabecular bone volume increased, whereas the epiphyseal trabecular bone volume tended to decrease, enhancing both bone resorption and formation.
    2 context sentences
    Summary · context
    Continuous infusion of hPTH(1-34) caused a dose-dependent decrease in the dry weight of the femur and a hyperparathyroidism-like condition in the high-dose group (214 ng/kg/h).
    Summary · context
    We compared the effects of synthetic human parathyroid hormone (1-34) (hPTH[1-34]) on rat bones when administered by intermittent injection and by continuous infusion for 4 weeks.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In rats, high-dose continuous hPTH(1-34) infusion enhanced bone formation.

    In plain wordsIn rats, high-dose continuous hPTH infusion increased bone formation.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone formation with infusion
    Study

    ratn: not reported in source

    Rat bone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    214 ng/kg/h · continuous infusion · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    In this group, although bone morphology was quite abnormal, the metaphyseal trabecular bone volume increased, whereas the epiphyseal trabecular bone volume tended to decrease, enhancing both bone resorption and formation.
    2 context sentences
    Summary · context
    Continuous infusion of hPTH(1-34) caused a dose-dependent decrease in the dry weight of the femur and a hyperparathyroidism-like condition in the high-dose group (214 ng/kg/h).
    Summary · context
    We compared the effects of synthetic human parathyroid hormone (1-34) (hPTH[1-34]) on rat bones when administered by intermittent injection and by continuous infusion for 4 weeks.
  8. 08AnimalAnimal study (in vivo)Safety outcome

    In rats, continuous hPTH(1-34) infusion produced marked porosity of tibial diaphyseal cortical bone.

    In plain wordsIn rats, continuous hPTH infusion made the tibial shaft cortex markedly porous.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTibial cortical porosity with infusion
    Study

    ratn: not reported in source

    Rat bone
    Outcome group
    Adverse events · Musculoskeletal
    Studied dose
    214 ng/kg/h · continuous infusion · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    The diaphyseal cortical bone of the tibia became markedly porous, and this appeared to be the main cause of the decrease in total bone weight.
    3 context sentences
    Summary · context
    In this group, although bone morphology was quite abnormal, the metaphyseal trabecular bone volume increased, whereas the epiphyseal trabecular bone volume tended to decrease, enhancing both bone resorption and formation.
    Summary · context
    Continuous infusion of hPTH(1-34) caused a dose-dependent decrease in the dry weight of the femur and a hyperparathyroidism-like condition in the high-dose group (214 ng/kg/h).
    Summary · context
    We compared the effects of synthetic human parathyroid hormone (1-34) (hPTH[1-34]) on rat bones when administered by intermittent injection and by continuous infusion for 4 weeks.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In rats, intermittent hPTH(1-34) injections increased femoral dry weight dose dependently.

    In plain wordsIn rats, intermittent hPTH injections increased thigh bone dry weight with increasing dose.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseFemoral dry weight with intermittent injection
    Study

    ratn: not reported in source

    Rat bone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · intermittent injection · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    Conversely, the dry weight of the femur increased in a dose-dependent manner in the intermittent-injection groups.
    1 context sentence
    Summary · context
    We compared the effects of synthetic human parathyroid hormone (1-34) (hPTH[1-34]) on rat bones when administered by intermittent injection and by continuous infusion for 4 weeks.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In rats, cortical bone porosity was not observed with intermittent hPTH(1-34) injections.

    In plain wordsIn rats, cortical bone porosity was not observed with intermittent hPTH injections.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeCortical porosity with intermittent injection
    Study

    ratn: not reported in source

    Rat bone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · intermittent injection · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    Neither porosity of the cortical bone nor abnormal morphology of the trabecular bone was observed.
    1 context sentence
    Summary · context
    We compared the effects of synthetic human parathyroid hormone (1-34) (hPTH[1-34]) on rat bones when administered by intermittent injection and by continuous infusion for 4 weeks.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In rats, abnormal trabecular morphology was not observed with intermittent hPTH(1-34) injections.

    In plain wordsIn rats, abnormal spongy bone structure was not observed with intermittent hPTH injections.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeTrabecular morphology with intermittent injection
    Study

    ratn: not reported in source

    Rat bone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · intermittent injection · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    Neither porosity of the cortical bone nor abnormal morphology of the trabecular bone was observed.
    1 context sentence
    Summary · context
    We compared the effects of synthetic human parathyroid hormone (1-34) (hPTH[1-34]) on rat bones when administered by intermittent injection and by continuous infusion for 4 weeks.
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In rats, intermittent hPTH(1-34) increased metaphyseal trabecular bone volume while retaining normal morphology.

    In plain wordsIn rats, intermittent hPTH increased metaphyseal spongy bone volume while retaining normal structure.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseMetaphyseal trabecular volume with intermittent injection
    Study

    ratn: not reported in source

    Rat bone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · intermittent injection · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    The volume of the metaphyseal trabecular bone increased while retaining its normal morphology.
    1 context sentence
    Summary · context
    We compared the effects of synthetic human parathyroid hormone (1-34) (hPTH[1-34]) on rat bones when administered by intermittent injection and by continuous infusion for 4 weeks.
  13. 13AnimalAnimal study (in vivo)Efficacy outcome

    In rats, intermittent hPTH(1-34) increased epiphyseal trabecular bone formation.

    In plain wordsIn rats, intermittent hPTH increased bone formation in epiphyseal spongy bone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseEpiphyseal bone formation with intermittent injection
    Study

    ratn: not reported in source

    Rat bone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · intermittent injection · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    The epiphyseal trabecular bone formation obviously increased without increase in the number of osteoclasts.
    1 context sentence
    Summary · context
    We compared the effects of synthetic human parathyroid hormone (1-34) (hPTH[1-34]) on rat bones when administered by intermittent injection and by continuous infusion for 4 weeks.
  14. 14AnimalAnimal study (in vivo)Efficacy outcome

    In rats, intermittent hPTH(1-34) did not increase epiphyseal osteoclast number.

    In plain wordsIn rats, intermittent hPTH did not increase the number of bone breakdown cells in the epiphysis.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeEpiphyseal osteoclast number with intermittent injection
    Study

    ratn: not reported in source

    Rat bone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · intermittent injection · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    The epiphyseal trabecular bone formation obviously increased without increase in the number of osteoclasts.
    1 context sentence
    Summary · context
    We compared the effects of synthetic human parathyroid hormone (1-34) (hPTH[1-34]) on rat bones when administered by intermittent injection and by continuous infusion for 4 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.